Fluparoxan

Fluparoxan

SCHEMBL29401005

Fc1cccc2c1O[C@H]1CNC[C@@H]1O2

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 8/20 0.38
CHRNB2 P17787 2/20 0.38
CHRNA4 P43681 2/20 0.38
SLC6A4 P31645 2/20 0.38
SLC6A3 Q01959 2/20 0.38
CA2 P00918 1/20 0.38
HTR6 P50406 4/20 0.36
CHRNA7 P36544 1/20 0.34
HTR1A P08908 6/20 0.34
HTR2C P28335 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.31
ADRA1D P25100 2/20 0.31
ADRA1A P35348 2/20 0.31
ADRA1B P35368 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluparoxan SCHEMBL9570339 1.00 SLC6A2 (0.38) SLC6A2CHRNB2CHRNA4SLC6A4SLC6A3
Fluparoxan SCHEMBL7173629 1.00 SLC6A2 (0.38) SLC6A2CHRNB2CHRNA4SLC6A4SLC6A3
Fluparoxan SCHEMBL112164 1.00 SLC6A2 (0.38) SLC6A2CHRNB2CHRNA4SLC6A4SLC6A3
Fluparoxan SCHEMBL9482018 0.98 HTR6 (0.38) SLC6A2CHRNB2CHRNA4SLC6A4SLC6A3
Fluparoxan SCHEMBL122268 0.98 HTR6 (0.38) SLC6A2CHRNB2CHRNA4SLC6A4SLC6A3
Fluparoxan SCHEMBL9482026 0.98 HTR6 (0.38) SLC6A2CHRNB2CHRNA4SLC6A4SLC6A3
SCHEMBL10375117 0.82 BRD4 (0.36) SLC6A2CHRNB2CHRNA4SLC6A4SLC6A3
Hydrochloric Acid SCHEMBL10579193 0.81 BRD4 (0.36) SLC6A2SLC6A4SLC6A3HTR6HTR2C
SCHEMBL10376272 0.81 CHRNB2 (0.34) SLC6A2CHRNB2CHRNA4SLC6A4SLC6A3
SCHEMBL10375154 0.81 CHRNB2 (0.34) SLC6A2CHRNB2CHRNA4SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4706683-A2 CHEWABLE FORMULATIONS Elanco Tiergesundheit AG (CH) 2026-03-11 EP disclosed
US-20230277448-A1 CHEWABLE FORMULATIONS ELANCO TIERGESUNDHEIT AG (CH) 2023-09-07 US disclosed
CN-116685327-A Orphan nuclear receptor modulators for the treatment of pancreatitis, glioblastoma, sarcopenia and stroke 埃默里大学 2023-09-01 CN disclosed
CN-116507327-A Chewable formulations 礼蓝动物保健有限公司 2023-07-28 CN disclosed
EP-4208155-A1 CHEWABLE FORMULATIONS Elanco Tiergesundheit AG (CH) 2023-07-12 EP disclosed
CN-115269876-A Method, device and medium for extracting action relationship between chemical and protein 苏州大学 2022-11-01 CN disclosed
WO-2022049149-A1 CHEWABLE FORMULATIONS ELANCO TIERGESUNDHEIT AG (CH) 2022-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230277448-A1 CHEWABLE FORMULATIONS SI, TAS2R39, TAS2R31 SLC6A2 3849/4885CHRNB2 2145/4885CHRNA4 1625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.